Sponsors

Detection of colorectal cancer

A revolutionary test for the detection of mutations associated with colorectal cancer has been launched by Randox. This early, patient-friendly test allows the analysis of DNA in stool samples without the need for dietary or medication changes.

Some 90% of colorectal cancers can be cured if caught at an early stage. Early diagnosis is essential for improvement of patient prognosis, and screening programmes have already been implemented throughout Europe.

However, it is thought that chromosomal instability accounts for 85% of sporadic colorectal cancers. Therefore, the ability to screen for point mutations from this pathway using the Randox test in a patient presenting with a positive faecal occult blood test would be a valuable aid to the screening process by providing a highly specific test that may also benefit from increased patient compliance.

The DNA array from Randox allows the detection of 28 mutations associated with the chromosomal instability pathway. It is hoped that this revolutionary test will increase early detection of cancer and precancerous lesions and thus reduce the level of mortality associated with colorectal cancer.

Randox Laboratories www.randox.com

Latest Issues

Pathology Visions 24

Hyatt Regency, Orlando, FL
3-5 November, 2025

UK NEQAS Cellular Pathology Technique - Annual Participant’s Meeting

America Square Conference Centre, London, EC3N 2LB.
4 - 5 November, 2024

Medica

Messe Dusseldorf
11-14 November, 2024

POCT-for-Scot: Bringing the future to you

SEC Arena, Glasgow
14 November, 2024

Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo

Hyatt Regency, Vancouver, Canada
19-23 November, 2024